Novartis unit buys rights to ThromboGenics eye drug
Belgian biopharma company ThromboGenics (Euronext Brussels: THR) revealed this morning that it has entered into an agreement with Alcon, the ophthalmic subsidiary of Swiss drug major Novartis (NOVN: VX), for the commercialization of ocriplasmin, an investigational compound for the treatment of symptomatic vitreomacular adhesion (VMA) including macular hole, in all markets outside the USA.
As a result of this deal, ThromboGenics confirmed recent comments that it will concentrate on commercializing ocriplasmin in the USA, where it plans to build its commercial and medical organization to support the product’s anticipated launch within the next 12 months (The Pharma Letter March 12). Following discussions with the US Food and Drug Administration, the company will resubmit the Biologic License Application for the drug in April 2012 in order to meet the FDA’s timelines for Priority Review.
Deal worth a potential 375 million euros
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Biotechnology
| Headless Content Management with Blaze